glp 1 drugs and bipolar disorder GLP-1 receptor agonists show promise in treating substance use disorders Is tirzepatide (dual GIP/GLP‑1 receptor

However, many may not be aware that semaglutide has been available in oral form since it was approved by the FDA in 2019

Hyperbaric practitioners may want to alert their colleagues in ophthalmology that HBOT might be beneficial, and that if medically appropriate, HBOT may be worth offering to patients impacted by NAION

Yes, chronic constipation can potentially lead to haemorrhoids, anal fissures, faecal impaction, or rectal prolapse, making it important to address symptoms promptly

TRIUMPH-1 Phase 3 Trial Results Eli Lilly announced the TRIUMPH-1 results on May 21, 2026, emphasizing Retatrutide's effectiveness

Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk

The reason why the prevalence of the NA-DKD phenotype is on the rise is still unclear